Trump Tariffs: Indian Pharma Dodges Bullet, But Sword May Remain

Question About Costs For Firms With US Manufacturing

 
• By Vibha Ravi

Trump announced a 26% reciprocal tariff on India, but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?

US Tariffs Are Causing A Flutter Across The World
US tariffs are raising economic concerns around the world. (Shutterstock)

More from Manufacturing

More from Legislation